The U.S. Food and Drug Administration (FDA) has granted fast-track status to CUSP06, Oncusp Therapeutics’ treatment candidate for platinum-resistant ovarian cancer. This designation…
News
A triple-combination therapy using tuspetinib, Aptose Biosciences‘ experimental oral therapy, is showing potential in treating adults with newly diagnosed acute myeloid leukemia (AML),…
A new blood test called PAC-MANN can detect the most common type of pancreatic cancer with high accuracy, according to a study led by…
An experimental immune-modulating therapy called KROS 101 was able to activate immune cells to kill glioma cells in laboratory experiments, according to new preclinical…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Gradalis’ experimental immunotherapy platform Vigil (Gemogenovatucel-T) as…
A first patient with relapsed/refractory multiple myeloma (RRMM) treated with CT0590, Carsgen Therapeutics’ CAR T-cell therapy, showed a complete response to the…
Treatment with the cancer vaccine galinpepimut-S (GPS) is showing promise to potentially improve survival in people with acute myeloid leukemia (AML), a type of…
Certain immunotherapies may be effective in some cases of pancreatic neuroendocrine neoplasms (Pan-NEN), a rare type of pancreatic cancer, according to a study that…
The Lundin Cancer Fund has donated $4 million to the Canadian Cancer Society to create the Glioblastoma Research Program, a five-year initiative to…
About a third of women with cyclin E1+ platinum-resistant ovarian cancer (PROC) responded to treatment with azenosertib, an experimental therapy by Zentalis. That’s according…
